Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 28.89 -3.54% -1.06
PTLA closed down 3.54 percent on Tuesday, August 20, 2019, on 88 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
Stochastic Sell Signal Bearish -3.54%
NR7 Range Contraction -3.54%
Multiple of Ten Bearish Other -3.54%
Inside Day Range Contraction -3.54%

Older signals for PTLA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Medicine Biopharmaceutical Clinical Medicine Surgery Inflammation Seattle Genetics Spinal Muscular Atrophy Inflammatory Disorders Thrombosis Astellas Pharma Anticoagulants Factor X Hematologic Disorders Portola Pharmaceuticals
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 37.95
52 Week Low 14.81
Average Volume 1,115,651
200-Day Moving Average 27.485
50-Day Moving Average 27.1238
20-Day Moving Average 28.0315
10-Day Moving Average 29.976
Average True Range 1.3788
ADX 20.24
+DI 25.455
-DI 24.9281
Chandelier Exit (Long, 3 ATRs ) 27.5936
Chandelier Exit (Short, 3 ATRs ) 28.0464
Upper Bollinger Band 32.3128
Lower Bollinger Band 23.7502
Percent B (%b) 0.6
BandWidth 30.54635
MACD Line 0.9177
MACD Signal Line 0.7281
MACD Histogram 0.1896
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -6.35
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.60
Resistance 3 (R3) 30.73 30.29 30.32
Resistance 2 (R2) 30.29 29.85 30.23 30.22
Resistance 1 (R1) 29.59 29.59 29.37 29.46 30.12
Pivot Point 29.15 29.15 29.04 29.09 29.15
Support 1 (S1) 28.45 28.71 28.23 28.32 27.66
Support 2 (S2) 28.01 28.45 27.95 27.56
Support 3 (S3) 27.31 28.01 27.47
Support 4 (S4) 27.18